Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors
Completed
Pfizer
Phase 4
2007-03-01
To investigate whether a Caduet based treatment strategy might result in greater reduction in
total cardiovascular risk as compared to usual care in subjects with hypertension and
additional risk factors.
Caduet vs Usual Care in Subjects With Hypertension and Additional Risk Factors
Completed
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 4
2007-03-01
To investigate whether a Caduet based treatment strategy might result in greater reduction in
total cardiovascular risk as compared to usual care in subjects with hypertension and
additional risk factors.
A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk
Completed
Pfizer
Phase 4
2007-01-01
The purpose of this study is to investigate whether an aggressive multi-risk factor
management strategy (Caduet plus therapeutic lifestyle changes (TLC) regimen) will result in
greater percentage of patients achieving blood pressure and low density lipoprotein
cholesterol (LDL-C) goals compared with a Joint National Committee 7/ National Cholesterol
Education Program Adult Treatment Panel III (JNC 7/NCEP ATP III) guideline-based approach
(Norvasc plus TLC regimen) after 6 weeks of treatment in primary prevention subjects with
hypertension and additional risk factors, including dyslipidemia.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
